拜玛林制药Voxzogo®获加拿大卫生部附条件批准 用于软骨发育不全症治疗

美股速递
Feb 11

拜玛林制药(Biomarin Pharmaceutical)近日宣布,其治疗软骨发育不全症的药物Voxzogo®已获得加拿大卫生部颁发的附条件合规通知。这一批准标志着该药物在加拿大市场迈出重要一步,为当地患者提供了新的治疗选择。

软骨发育不全症是一种罕见的遗传性疾病,主要特征为骨骼发育异常。Voxzogo®作为一种创新疗法,其获批将为符合特定条件的患者群体带来希望。加拿大卫生部的附条件批准通常基于药物显示的潜在临床效益,同时要求制药公司继续开展相关研究以进一步验证疗效与安全性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10